Skip to main content
. Author manuscript; available in PMC: 2022 Oct 28.
Published in final edited form as: J Antimicrob Chemother. 2022 Aug 29;77(11):3110–3117. doi: 10.1093/jac/dkac290

Table 2.

Spearman’s rank-order correlations for dolutegravir AUC0-24 estimates and change in modified mini screen score and sleep quality form baseline to weeks 4, 12, and 24

  Spearman’s rank-order correlation for dolutegravir AUC0-24 and change in MMS form baseline Spearman’s rank-order correlation for dolutegravir AUC0-24 and change in sleep quality form baseline
Time Point n rs 95% CI p-value n rs 95% CI p-value
Week 4 461 -0.062 -0.153 to 0.029 0.186 419 -0.036 -0.127 to 0.056 0.468
Week 12 461 -0.099 -0.188 to -0.011 0.033 411 -0.101 -0.201 to -0.001 0.041
Week 24 461 -0.129 -0.222 to -0.036 0.006 418 0.002 -0.098 to 0.101 0.968

AUC0-24 = area under the concentration-time curve, MMS = modified mini score, rs = Spearman’s rank-order correlation